07 November 2026
Table of Contents
Immunotherapy has changed the outlook for several cancers, and colorectal cancer is one of the more interesting examples — because unlike some other cancers, its benefit here isn’t universal. Here’s the honest answer: immunotherapy can be genuinely transformative for a specific subset of colorectal cancer patients, while offering limited benefit on its own for others. Knowing which group applies to a specific case changes everything about how it’s used.
Let’s walk through this together. This guide explains how immunotherapy works for colorectal cancer, the biomarker that determines who’s likely to benefit, and where it fits into the broader treatment picture.
How Colorectal Cancer Has Traditionally Been Treated
Colorectal cancer treatment has long centred on surgery to remove the tumour, often combined with chemotherapy, and sometimes radiation depending on the location and stage of the disease. For many patients, this combination remains the standard and most effective approach.
Targeted therapies aimed at specific genetic features of a tumour have also become part of the picture over recent years, and immunotherapy has more recently carved out a distinct, if selective, role of its own.
How Immunotherapy Works Differently
Rather than directly attacking cancer cells the way chemotherapy does, immunotherapy works by helping a patient’s own immune system recognise cancer cells as a threat and mount an attack against them. Many tumours develop ways of hiding from the immune system; immunotherapy drugs, particularly a class called checkpoint inhibitors, help remove that camouflage.
KEY FACT
Immunotherapy tends to work best against tumours that carry a large number of genetic mutations, since these mutations make cancer cells look more clearly “foreign” to the immune system, giving it more to recognise and target.
The Biomarker That Changes Everything
The single most important factor in predicting whether a colorectal cancer will respond to immunotherapy is a tumour characteristic called microsatellite instability, or MSI status, closely linked to a related marker called mismatch repair (MMR) deficiency. Tumours described as MSI-High or MMR-deficient carry a particularly large number of mutations, which tends to make them far more visible and vulnerable to an immune-system-based attack.
Testing for this marker is now considered a standard part of working up a colorectal cancer diagnosis, precisely because it so directly shapes whether immunotherapy is a meaningful option.
Who Is Most Likely to Benefit
Patients whose colorectal cancer tests as MSI-High or MMR-deficient are the clearest candidates for immunotherapy, and for this group, the treatment has shown meaningful, sometimes durable, responses — including for advanced or metastatic disease that has proven difficult to control with chemotherapy alone.
- Patients with MSI-High or MMR-deficient tumours, confirmed through biomarker testing
- Patients with advanced or metastatic colorectal cancer where this biomarker is present
- Select patients being considered for immunotherapy earlier in their treatment course, based on this same biomarker
Where Immunotherapy Fits in the Treatment Journey
For eligible patients, immunotherapy may be used at different points depending on the specific clinical picture — sometimes for advanced disease that has progressed on other treatments, and increasingly, for eligible patients, earlier in the treatment course. Where exactly it fits depends on the individual case, disease stage, and biomarker findings.
Who May Not Benefit as Much From Immunotherapy Alone
IMPORTANT
Most colorectal cancers are classified as MSS, or microsatellite stable — meaning they don’t carry the same high mutation burden. For this larger group of patients, immunotherapy alone has generally shown limited benefit, and chemotherapy-based approaches typically remain the mainstay of treatment.
This is an active area of ongoing research, including approaches that combine immunotherapy with other treatments to try to extend its benefit to MSS tumours as well. For now, though, biomarker status remains the clearest guide to who is likely to respond.
MSI-High vs MSS Tumours at a Glance
| Tumour Type | Immunotherapy Response | Typical Approach |
|---|---|---|
| MSI-High / MMR-deficient | Often responds meaningfully to immunotherapy | Immunotherapy considered as part of the treatment plan |
| MSS (microsatellite stable) | Limited response to immunotherapy alone | Chemotherapy-based approaches remain the mainstay |
Frequently Asked Questions
Testing for MSI/MMR status is now widely recommended as standard practice at diagnosis, since it meaningfully shapes treatment decisions, including whether immunotherapy is a relevant option.
For MSS tumours, immunotherapy alone has generally shown limited benefit, though research into combination approaches is ongoing. Your oncologist can explain what current evidence supports for your specific case.
This depends on the specific case and biomarker status. Some patients may receive a combination approach, while for others chemotherapy alone or immunotherapy alone may be more appropriate.
It represents a smaller subset of colorectal cancers overall, which is exactly why biomarker testing matters — it identifies the specific patients most likely to benefit from immunotherapy.
MSI-High status can be associated with certain hereditary conditions, so a positive result sometimes prompts further genetic evaluation. Your care team can guide you on whether this applies to your situation.
Outcomes vary by individual case and disease stage. Immunotherapy has shown meaningful and sometimes durable responses for eligible patients, but your oncologist can give you a clearer picture based on your specific diagnosis.
A Final Word
Immunotherapy’s role in colorectal cancer is a good example of why modern cancer care increasingly starts with biomarker testing rather than a one-size-fits-all approach. What this means for you is that whether immunotherapy is relevant to your treatment depends on a specific, testable characteristic of your tumour — not a guess, and not a universal rule.
If you’d like to understand whether immunotherapy could be relevant to your specific diagnosis, speaking with an oncologist about biomarker testing is the clearest next step.
